Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:CMPX NASDAQ:ONCY NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$8.00-2.8%$7.43$6.10▼$28.67$570.39M1.47303,408 shs272,903 shsCMPXCompass Therapeutics$3.61-1.6%$3.29$1.27▼$4.08$507.50M1.481.69 million shs1.81 million shsONCYOncolytics Biotech$1.35-0.7%$1.15$0.33▼$1.51$136.49M1.241.23 million shs810,570 shsPRTAProthena$10.17+3.1%$8.40$4.32▼$18.88$530.76M-0.11741,614 shs1.03 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-1.67%+8.15%+14.94%+9.73%-65.13%CMPXCompass Therapeutics-0.81%-3.93%+6.69%+38.49%+90.16%ONCYOncolytics Biotech-1.45%-3.55%+28.30%+8.80%+23.64%PRTAProthena-0.60%+1.02%+15.32%+51.23%-41.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$8.00-2.8%$7.43$6.10▼$28.67$570.39M1.47303,408 shs272,903 shsCMPXCompass Therapeutics$3.61-1.6%$3.29$1.27▼$4.08$507.50M1.481.69 million shs1.81 million shsONCYOncolytics Biotech$1.35-0.7%$1.15$0.33▼$1.51$136.49M1.241.23 million shs810,570 shsPRTAProthena$10.17+3.1%$8.40$4.32▼$18.88$530.76M-0.11741,614 shs1.03 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics-1.67%+8.15%+14.94%+9.73%-65.13%CMPXCompass Therapeutics-0.81%-3.93%+6.69%+38.49%+90.16%ONCYOncolytics Biotech-1.45%-3.55%+28.30%+8.80%+23.64%PRTAProthena-0.60%+1.02%+15.32%+51.23%-41.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.50Moderate Buy$22.22177.78% UpsideCMPXCompass Therapeutics 2.91Moderate Buy$13.10262.88% UpsideONCYOncolytics Biotech 2.50Moderate Buy$5.00270.37% UpsidePRTAProthena 2.20Hold$20.50101.57% UpsideCurrent Analyst Ratings BreakdownLatest ONCY, CMPX, BCYC, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/7/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $20.0010/6/2025CMPXCompass TherapeuticsCompass PointSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.0010/6/2025CMPXCompass TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.009/27/2025BCYCBicycle TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ONCYOncolytics BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PRTAProthenaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/2/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$29.00 ➝ $11.008/28/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$81.00 ➝ $15.008/28/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/13/2025ONCYOncolytics BiotechLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$35.28M15.72N/AN/A$11.48 per share0.70CMPXCompass Therapeutics$850K587.28N/AN/A$0.91 per share3.97ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/APRTAProthena$135.16M4.05N/AN/A$9.05 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$169.03M-$3.51N/AN/AN/A-1,257.00%-32.43%-26.80%10/30/2025 (Estimated)CMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)PRTAProthena-$122.31M-$5.64N/AN/AN/A-2,929.30%-62.17%-54.43%11/11/2025 (Estimated)Latest ONCY, CMPX, BCYC, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025BCYCBicycle Therapeutics-$1.05N/AN/AN/AN/AN/A8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A8/8/2025Q2 2025BCYCBicycle Therapeutics-$0.95-$1.14-$0.19-$1.14$9.43 million$2.90 million8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/A8/4/2025Q2 2025PRTAProthena-$1.11-$1.86-$0.75-$2.34$5.36 million$4.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A10.3910.39CMPXCompass TherapeuticsN/A7.667.66ONCYOncolytics BiotechN/A2.882.88PRTAProthenaN/A5.685.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%CMPXCompass Therapeutics68.43%ONCYOncolytics Biotech6.82%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics8.50%CMPXCompass Therapeutics29.80%ONCYOncolytics Biotech0.10%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.31 million63.42 millionOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionablePRTAProthena13053.83 million48.88 millionOptionableONCY, CMPX, BCYC, and PRTA HeadlinesRecent News About These CompaniesDeep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)4 hours ago | benzinga.comPublic Employees Retirement System of Ohio Invests $256,000 in Prothena Corporation plc $PRTAOctober 7 at 3:17 AM | marketbeat.comProthena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comProthena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of ...October 1, 2025 | pharmiweb.comPProthena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's DiseaseOctober 1, 2025 | businesswire.comProthena (NASDAQ:PRTA) Stock Price Passes Below 200 Day Moving Average - Should You Sell?September 23, 2025 | marketbeat.comGoldman Sachs Group Inc. Decreases Position in Prothena Corporation plc $PRTASeptember 16, 2025 | marketbeat.comWhat is Zacks Research's Estimate for Prothena Q1 Earnings?September 16, 2025 | marketbeat.comSiren L.L.C. Grows Stock Holdings in Prothena Corporation plc $PRTASeptember 13, 2025 | marketbeat.comProthena Down 40% Year to Date: What Lies Ahead for the Stock?September 11, 2025 | zacks.comProthena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 9, 2025 | marketbeat.comProthena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?September 3, 2025 | zacks.comProthena provides mixed update on PRX012August 30, 2025 | thepharmaletter.comTProthena Corporation plc: Prothena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | finanznachrichten.deProthena to Participate in the Cantor Fitzgerald Global Healthcare ConferenceAugust 28, 2025 | businesswire.comProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical ProgramAugust 27, 2025 | businesswire.comCitizens JMP Remains a Buy on Prothena (PRTA)August 9, 2025 | theglobeandmail.comNovo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns HopefulAugust 7, 2025 | msn.comProthena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with CardiomyopathyAugust 6, 2025 | businesswire.com9 Analysts Assess Prothena Corp: What You Need To KnowAugust 5, 2025 | benzinga.comProthena Reports Q2 2025 Financial Results and Pipeline ProgressAugust 4, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCY, CMPX, BCYC, and PRTA Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$8.00 -0.23 (-2.79%) Closing price 04:00 PM EasternExtended Trading$7.98 -0.02 (-0.25%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.Compass Therapeutics NASDAQ:CMPX$3.61 -0.06 (-1.63%) Closing price 04:00 PM EasternExtended Trading$3.65 +0.04 (+1.08%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Oncolytics Biotech NASDAQ:ONCY$1.35 -0.01 (-0.74%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.01 (+1.11%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Prothena NASDAQ:PRTA$10.17 +0.31 (+3.14%) Closing price 04:00 PM EasternExtended Trading$9.88 -0.29 (-2.85%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
